Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma
ChiCTR1900022969Phase 4Not yet recruiting
- Sponsor
- Guiping People's Hospital
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of anlotinib in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Guiping People's Hospital. Primary endpoint: Failure-free survival. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1900022969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022969.